Clene Inc. Announces Accelerated FDA Pathway for ALS Drug Application

Key Highlights from the SEC Filing

• Successful FDA Meeting: Clene Inc. held a pivotal in-person Type C meeting with the U.S. Food and Drug Administration (FDA) regarding its lead drug candidate, CNM-Au8, for amyotrophic lateral sclerosis (ALS).
• Accelerated Approval New Drug Application (NDA): Following the meeting, Clene announced its intention to file an NDA for CNM-Au8 under the FDA’s accelerated approval pathway for ALS.
• FDA Endorsement: The FDA stated that Clene’s “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway for the treatment of ALS.”
• Biomarker Data: FDA acknowledged that neurofilament light (NfL) biomarker data could potentially serve as a “reasonably likely surrogate endpoint,” a significant regulatory milestone for CNM-Au8.
• Final Meeting Minutes: Clene received final minutes confirming the FDA’s positive stance on the potential for its biomarker-driven NDA submission.
• Stock Information: Clene’s common stock trades on Nasdaq under the symbol “CLNN”.
• Next Steps: Clene plans to submit the NDA and initiate a Phase 3 trial in ALS, pending FDA review and approval.

Details and Implications for Shareholders

This SEC Form 8-K filing contains material news that is highly relevant to Clene Inc. shareholders and the broader investment community:

• Regulatory Inflection Point: The FDA’s willingness to consider NfL as a surrogate endpoint under accelerated approval may dramatically shorten the timeline for CNM-Au8 to reach the market, potentially transforming Clene’s commercial outlook.
• Potential Share Price Impact: The announcement of accelerated approval prospects for a novel ALS therapy is likely to be price sensitive. ALS is a high-need, high-profile neurodegenerative disease, and regulatory progress typically drives investor sentiment and valuation for biotech companies.
• Risk Disclosure: While the FDA’s feedback is positive, actual approval will depend on the strength of Clene’s submission, ongoing clinical trial results, and future regulatory reviews. The company warns of risks related to clinical efficacy, regulatory actions, funding requirements, and market conditions. Investors should monitor further updates, including the NDA submission and Phase 3 trial initiation.
• Notable Management Statement: The report is signed by CEO Robert Etherington, underscoring the importance of this regulatory event for Clene’s executive team and strategic direction.

Investor Contacts

For further information:

Investor Contact: Kevin Gardner, LifeSci Advisors ([email protected]; 617-283-2856)

Media Contact: Caroline Wagner, Forbes Tate Partners ([email protected]; (267) 294-6563)

Forward-Looking Statements Disclaimer

This article contains forward-looking statements based on Clene Inc.’s SEC filings and press releases. Actual results may differ materially due to factors including but not limited to clinical trial outcomes, regulatory decisions, funding availability, and market conditions. Investors are advised to review Clene’s filings, including annual and quarterly reports, and consult with financial professionals before making investment decisions. All information is as of the date of publication and may be updated by subsequent events.

View Clene Inc. Historical chart here